Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Iowa Austedo Prior Auth Policy | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.04.87

    Austedo and Austedo XR (deutetrabenazine) Coverage

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.04.87 alerts

    Get alerted when Policy 05.04.87 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization coverage for Austedo and Austedo XR in adults with chorea associated with Huntington's disease or tardive dyskinesia, subject to clinical criteria, documentation, specialist requirements, and dosing or quantity limits.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyAustedo and Austedo XR (deutetrabenazine) Coverage
    Policy CodePolicy 05.04.87
    Change TypeNo material clinical or coverage changes
    Effective DateSeptember 30, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot specified
    Key ActionSubmit indication-specific clinical documentation and ensure the medication is prescribed by or in consultation with the required specialist for initial prior authorization requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2FDA-approved covered indications
    12 monthsInitial authorization duration
    12 monthsContinuation authorization duration
    36 CAG repeatsMinimum HTT CAG repeat sequence

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    48 mg/dayMaximum recommended daily dosage

    Coverage Criteria

    Initial Therapy: Chorea Associated With Huntington's Disease

    Covered when all of the following are met:

    Huntington's disease chorea initial approval

    • Required findings: Member demonstrates characteristic motor examination features.
    • ONE of

      • Genetic finding: Laboratory results indicate an expanded HTT CAG repeat sequence of at least 36.at least 36
      • Family history: Member has a positive family history for Huntington's disease.

    Initial Therapy: Tardive Dyskinesia

    Covered when all of the following are met:

    Tardive dyskinesia initial approval

    • Clinical manifestations: Member exhibits clinical manifestations of tardive dyskinesia.
    • Clinical assessment: Member's tardive dyskinesia has been assessed through clinical examination or with a structured evaluative tool, such as AIMS or DISCUS.

      Examples include the Abnormal Involuntary Movement Scale and Dyskinesia Identification System: Condensed User Scale.

    Continuation Therapy

    Covered when all of the following are met:

    Continuation therapy: Member has an indication listed in the initial approval criteria and is experiencing benefit from therapy, evidenced by disease stability or disease improvement.

    Authorization may be granted for 12 months.

    Austedo and Austedo XR are not covered as medically necessary for members who do not meet the applicable approval criteria or who have exclusions to the prescribed therapy.

    Austedo and Austedo XR are considered not medically necessary when the member does not meet the criteria set forth in this policy.

    Coding and Clinical Thresholds

    Procedures and Billing Codesmixed
    N/ANo specific procedure or billing codes listed.
    Expanded HTT CAG repeat sequence
    MeasureExpanded HTT CAG repeat sequence
    Minimum thresholdAt least 36 CAG repeats
    ApplicationLaboratory support for Huntington's disease in an adult member with chorea
    Maximum recommended daily dosage
    MedicationAustedo and Austedo XR (deutetrabenazine)
    Maximum recommended daily dosage48 mg per day
    Titration contextDosage may be increased at weekly intervals in increments of 6 mg per day

    Prior Authorization and Provider Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Austedo (deutetrabenazine) or Austedo XR (deutetrabenazine extended release). For initial requests, submit indication-specific documentation and confirm that all applicable approval criteria and prescriber requirements are met.

    • For Huntington's disease chorea, the member must be an adult who demonstrates characteristic motor examination features and has either an expanded HTT CAG repeat sequence of at least 36 or a positive family history for Huntington's disease.
    • For tardive dyskinesia, the member must be an adult who exhibits clinical manifestations of the disease and has been assessed through clinical examination or a structured evaluative tool, such as AIMS or DISCUS.
    • The medication must be prescribed by or in consultation with a neurologist or a specialist in treatment of Huntington's disease chorea; for tardive dyskinesia, the prescriber must be a neurologist, psychiatrist, or specialist in treatment of tardive dyskinesia.
    • Initial authorization, when approved, may be granted for 12 months.
    Documentation Required

    Policy Background

    Deutetrabenazine products Austedo and Austedo XR are covered under this policy for adults with chorea associated with Huntington's disease or tardive dyskinesia. Coverage requires objective clinical support for the applicable condition, including characteristic motor examination features for Huntington's disease chorea or documented clinical manifestations and assessment for tardive dyskinesia.

    Definitions and Assessment Tools

    Structured evaluative tool
    DefinitionA structured evaluative tool used to assess tardive dyskinesia
    Example 1Abnormal Involuntary Movement Scale (AIMS)
    Example 2Dyskinesia Identification System: Condensed User Scale (DISCUS)

    Initial Therapy Authorization

    Initial Therapy: Huntington's Disease Chorea

    Authorization of 12 months may be granted when all of the following are met:

    Chorea associated with Huntington's disease

    • Motor findings: Member demonstrates characteristic motor examination features.
    • ONE of

      • Laboratory results indicate an expanded HTT CAG repeat sequence of at least 36.at least 36
      • Family history: Member has a positive family history for Huntington's disease.

    Continuation Therapy Authorization

    Continuation Therapy

    Continuation authorization may be granted when all of the following are met:

    Continuation of therapy: Member has an indication listed in the initial approval criteria and is experiencing benefit from therapy as evidenced by disease stability or disease improvement.

    Authorization duration is 12 months.

    Product-Specific Quantity Limits

    Austedo 6 mg tablet
    ProductAustedo 6 mg tablet
    Standard limit60 tablets
    Limit periodPer 30 days
    Austedo 9 mg tablet
    ProductAustedo 9 mg tablet
    Standard limit120 tablets
    Limit periodPer 30 days
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyAustedo and Austedo XR (deutetrabenazine) Coverage
    Policy CodePolicy 05.04.87
    Change TypeNo material clinical or coverage changes
    Effective DateSeptember 30, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot specified
    Key ActionSubmit indication-specific clinical documentation and ensure the medication is prescribed by or in consultation with the required specialist for initial prior authorization requests.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsPrior Authorization and Provider RequirementsPolicy BackgroundDefinitions and Assessment ToolsInitial Therapy AuthorizationContinuation Therapy AuthorizationProduct-Specific Quantity Limits

    Huntington's Disease Chorea Documentation

    For initial requests to treat chorea associated with Huntington's disease, submit chart notes or medical record documentation supporting the diagnosis and characteristic motor examination features.

    • Documentation must describe the characteristic motor examination features associated with Huntington's disease chorea.
    Documentation Required

    Tardive Dyskinesia Documentation

    For initial requests to treat tardive dyskinesia, submit chart notes or medical record documentation supporting the clinical manifestations of the disease.

    • Documentation should support assessment through clinical examination or a structured evaluative tool, such as the Abnormal Involuntary Movement Scale (AIMS) or Dyskinesia Identification System: Condensed User Scale (DISCUS).
    Denial Risk

    Failure to Meet Clinical Criteria

    Requests may be denied when the member does not satisfy the applicable initial approval criteria or when continuation of therapy is not supported by clinical benefit.

    • For Huntington's disease chorea, denial may result when characteristic motor examination features are not documented or when neither an expanded HTT CAG repeat sequence of at least 36 nor a positive family history is present.
    • For tardive dyskinesia, denial may result when clinical manifestations are not documented or when the condition has not been assessed through clinical examination or a structured evaluative tool.
    • For continuation requests, the member must have an indication listed in the initial approval criteria and demonstrate benefit through disease stability or disease improvement.
    Denial Risk

    Policy Criteria or Exclusion Not Satisfied

    Austedo and Austedo XR are considered not medically necessary when the member does not meet the policy criteria. Coverage also requires that the member have no exclusions to the prescribed therapy.

    • Do not submit the therapy as medically necessary when the applicable indication, documentation, prescriber, or clinical approval criteria are not satisfied.
    • Review the member's benefits for exclusions before requesting authorization.

    Initial Therapy: Tardive Dyskinesia

    Authorization of 12 months may be granted when all of the following are met:

    Tardive dyskinesia

    • Clinical manifestations: Member exhibits clinical manifestations of disease.
    • Assessment: Member's tardive dyskinesia has been assessed through clinical examination or with a structured evaluative tool.
    Austedo 12 mg tablet
    ProductAustedo 12 mg tablet
    Standard limit120 tablets
    Limit periodPer 30 days
    Austedo XR 6 mg tablet
    ProductAustedo XR 6 mg tablet
    Standard limit90 tablets
    Limit periodPer 30 days
    Austedo XR 12 mg tablet
    ProductAustedo XR 12 mg tablet
    Standard limit120 tablets
    Limit periodPer 30 days
    Austedo XR 18 mg tablet
    ProductAustedo XR 18 mg tablet
    Standard limit30 tablets
    Limit periodPer 30 days
    Austedo XR 24 mg tablet
    ProductAustedo XR 24 mg tablet
    Standard limit60 tablets
    Limit periodPer 30 days
    Austedo XR 30 mg tablet
    ProductAustedo XR 30 mg tablet
    Standard limit30 tablets
    Limit periodPer 30 days
    Austedo XR 36 mg tablet
    ProductAustedo XR 36 mg tablet
    Standard limit30 tablets
    Limit periodPer 30 days
    Austedo XR 42 mg tablet
    ProductAustedo XR 42 mg tablet
    Standard limit30 tablets
    Limit periodPer 30 days
    Austedo XR 48 mg tablet
    ProductAustedo XR 48 mg tablet
    Standard limit30 tablets
    Limit periodPer 30 days
    Austedo XR Titration Kit: 6 mg, 12 mg, and 24 mg tablets
    ProductAustedo XR Titration Kit with 6 mg, 12 mg, and 24 mg tablets
    Standard limit1 kit (42 tablets)
    Limit periodPer 28 days
    Austedo XR Titration Kit: 12 mg, 18 mg, 24 mg, and 30 mg tablets
    ProductAustedo XR Titration Kit with 12 mg, 18 mg, 24 mg, and 30 mg tablets
    Standard limit1 kit (28 tablets)
    Limit periodPer 28 days